

**OPEN ACCESS**

Repository of the Max Delbrück Center for Molecular Medicine (MDC)  
Berlin (Germany)  
<http://edoc.mdc-berlin.de/13874/>

## Long non-coding RNA in health and disease

---

*Maass, P.G., Luft, F.C., Baehring, S.*

## Long non-coding RNA in health and disease

Philipp G. Maass<sup>1,2,\*</sup>, Friedrich C. Luft<sup>1,2</sup> and Sylvia Bähring<sup>1,2</sup>

<sup>1</sup> Experimental and Clinical Research Center (ECRC), a joint cooperation between the Charité Medical Faculty and the Max Delbrück Center for Molecular Medicine (MDC), Lindenbergerweg 80, 13125 Berlin, Germany

<sup>2</sup> Max Delbrück Center for Molecular Medicine (MDC), Robert-Rössle-Strasse 10, 13125 Berlin, Germany

\* Corresponding author:

Philipp G. Maass, Ph.D.

Robert-Rössle-Strasse 10

13125 Berlin, Germany

Phone: +49 30 9406 2503

Fax: +49 30 9406 2536

[philipp.maass@mdc-berlin.de](mailto:philipp.maass@mdc-berlin.de)

word count main text with Table 1: 3986

## **Summary**

Long non-coding RNA (lncRNAs) interact with the nuclear architecture and are involved in fundamental biological mechanisms, such as imprinting, histone-code regulation, gene activation, gene repression, lineage determination, and cell proliferation, all by regulating gene expression. Understanding lncRNAs regulation of transcriptional or posttranscriptional gene regulation expands our knowledge of disease. Several associations between altered lncRNAs function and gene expression have been linked to clinical disease phenotypes. Early advances have been made in developing lncRNAs as biomarkers. Several mouse models reveal that human lncRNAs have very diverse functions. Their involvement in gene and genome regulation as well as disease underscores the importance of lncRNA-mediated regulatory networks. Because of their tissue-specific expression potential, their function as activators or repressors, and their selective targeting of genes, lncRNAs are of potential therapeutic interest. We review the regulatory mechanisms of lncRNAs, their major functional principles, and discuss their role in Mendelian disorders, cancer, cardiovascular disease, and neurological disorders.

## **Keywords**

Gene regulation, chromatin loop, in-cis, in-trans, histone code, transcriptional regulation, long non-coding RNA, lncRNA, *CISTR-ACT*, chromosomal territories, Waddington, Boveri

## Gene regulation

The principle of gene expression is based on epigenetic, transcriptional, and post-transcriptional regulation. Conrad Hal Waddington coined the term ‘epigenotype or epigenetics’ to summarize the complex developmental processes existing between phenotype and genotype in 1942 [1]. Today, we define epigenetics as the study of heritable changes in gene activity, which are not caused by changes in the DNA sequence. The genomic architecture and intra- or inter-chromosomal communication are key mechanisms for accurate gene regulation [2]. Post-transcriptional processes such as alternative splicing, RNA-editing, and microRNA-mediated regulation are reviewed elsewhere [3, 4].

Genomic regulators localized on one chromosome that act on the same chromosome are termed *cis*-regulatory elements. Elements regulating *in-trans* are interchromosomal regulators that communicate, either between homologous or non-homologous chromosomes. Enhancer elements activate gene expression, in contrast to silencers that suppress expression. Insulators determine barriers between different chromatin states (Fig. 1 a) and affect expression secondarily [5]. The gene-regulatory elements can exhibit high conservation; however, tissue-specific expression can differ greatly between species [6, 7]. The distance between the down- or upstream-located regulator and the target gene ranges several kilobases to 1.5 megabases (Mb) [8]. Functional protein complexes, namely transcription factors (TF) and co-activators, bind with chromatin modifying proteins at DNA consensus motifs. These motif complexes influence the gene expression. The nucleosome state is changed through ATP-dependent remodeling complexes of the SWitch/Sucrose NonFermentable (SWI/SNF) families (first found in yeast) or through histone modifiers, such as histone acetyl or methyl transferases [9, 10]. The tissue-specific expression is based on the chromatin state and the bound TF. Histones, the nucleoproteins around which the DNA is wrapped, and histone marks characterize the chromatin state. More than 60 different reversible and irreversible histone modifications are

known. They vary between tissues and species and determine the transcriptional active euchromatin or inactive heterochromatin states [11]. The histone modifications, especially during chromatin looping<sup>1</sup>, determine quantitatively the gene regulation.

Gene-regulatory elements (Fig. 1 b) are then in physical proximity to gene promoters to drive transcription [12]. Methylated alleles or gene clusters of either the maternal or paternal alleles in genomic imprinting processes and during X-inactivation to compensate gene dosage, become manifested in early embryogenesis [13]. The selection of activating or repressing histone marks was found to be operated by a sequential and combinatorial epigenetic code or language depending on the histone modifications involved, the DNA-binding proteins, and non-coding RNAs (ncRNAs), thereby assuring tissue-specific gene expression and epigenetic modifications [14, 15]. The combinatorial diversity is also due to the variety of functional gene-regulators, gene promoters, gene homologs or pseudo-genes, and embryonic and tissue-specific developmental stages. Inherited, framework or environmental epigenetic conditions determine systemically each functional element supporting proper gene regulation. Alterations of the complex interactions are often clinically apparent in numeric or structural aberrant karyotypes [16]. The physical dissociation of regulator and gene can cause positional effects leading to differentially expressed genes [17].

---

<sup>1</sup> Studying the structural properties and spatial organization of chromosomes is important for the understanding and evaluation of the regulation of gene expression, DNA replication and repair, and recombination. One example of chromosomal interaction is chromosome looping in which a chromosomal region can fold in order to bring an enhancer and associated TF within close proximity to a gene.

## **lncRNAs influence gene and genome regulation**

The Encyclopedia of DNA elements (ENCODE) consortium was founded in 2003 to characterize and annotate functional genomic elements of the human genome and of several transcriptomes. ENCODE determined that protein-coding genes are not the only major units of the genome that is nearly fully transcribed. Only <3% of the transcripts originate from protein-coding genes [18]. MicroRNAs (miRNAs), small interfering RNAs (siRNAs), and PIWI-interacting<sup>2</sup> RNAs (piRNAs), describe the class of short ncRNAs. In contrast, lncRNAs have more than 200 nucleotides, are intra- or intergenic, with or without a poly-A signal, oftentimes exhibit low expression levels, and can be highly tissue-specifically expressed and conserved [19, 20]. Linear ncRNAs and circular RNAs (circRNAs) have no protein-coding potential and can exist as mono- or multi-exonic sense and antisense transcripts [21, 22]. The circRNAs are post-transcriptional regulators that are formed by head-to-tail splicing. The first detailed investigation of the circular cerebellar degeneration-related protein 1 transcript (CDR1as) determined antagonistic actions on miRNA [22]. Chromatin immunoprecipitation with massively parallel DNA sequencing (ChIP-seq) experiments revealed that H3K4me1, H3K36me3, H3K27ac, and p300 characterize gene-activating enhancers and also lncRNAs loci [20, 23]. RNA sequencing (RNA-seq) of 24 human tissues identified more than 8000 lncRNAs that are typically co-expressed with their neighboring genes [19]. lncRNAs are tools for the gene and genome regulation within the nucleus [24]. Key roles of lncRNAs have been attributed to the biological processes, chromatin remodeling [25], X-chromosome inactivation [26], embryonic stem cell pluripotency [27], embryogenesis and development [28], as well as imprinting of genomic loci [13].

---

<sup>2</sup> The piwi or PIWI, originally P-element induced wimpy testis in *Drosophila*, class of genes was originally identified as encoding regulatory proteins responsible for maintaining incomplete differentiation in stem cells. PIWI proteins are highly conserved nucleic acid binding proteins.

Since 1991, the X-inactive specific transcript (*Xist*) has been investigated to gain insight into the mechanisms of X-chromosomal inactivation (XCI) [26]. In 2013, *Xist* was shown to exploit the three-dimensional structure of the X chromosome to spread from its transcription site to loci with high gene density and transcription that are in physical nuclear proximity. After the recruitment of the chromatin modifying polycomb group (PcG) proteins, *Xist* pulls up further *in cis* localized X-chromosomal regions to pursue inactivation through the formation of a transcriptionally silent H3K27me3 nuclear compartment and spreads dependent on its internal A-repeat domain across the entire X chromosome [29]. Another project explored the spreading mechanism of *Xist* on the 150 Mb of the X chromosome [30]. Simon and colleagues described a two-step inactivation mechanism. During the XCI establishment in early embryonic cells, *Xist* targets gene-rich domains before spreading to intervening gene-poor domains. The mechanism seem to persist as epigenetic memory for a facilitated and more efficient XCI during somatic proliferation and maintenance [30]. The active counterpart of *Xist* is *Tsix*, a gene that functions as an antisense to *Xist* to support the active X chromosome. Furthermore, the additional antagonistic relationship of *Xist* to *Jpx*, a lncRNA *Xist* activator, demonstrates that lncRNA-antisense transcripts regulate lncRNA [31, 32]. Also in 2013, Sun and colleagues showed that the lncRNA, *Jpx*, displaces the chromatin remodeling and RNA-binding protein, CTCF<sup>3</sup>, from one X chromosome to regulate the *Xist* expression in a titration-dependent antagonistic mechanism. Prior to XCI, CTCF normally inhibits the *Xist* expression. However, in the absence of CTCF, *Jpx* activates the *Xist* promoter [33]. In summary, these results broaden the classic understanding of how genes or chromosomes are regulated. The process of chromatin looping to establish gene expression functions *inter alia* through the actions of lncRNA and their associated proteins.

---

<sup>3</sup> Transcriptional repressor CTCF, also known as 11-zinc finger protein or CCCTC-binding factor, is a transcription factor that is involved in many cellular processes, including transcriptional regulation, insulator activity, and regulation of chromatin architecture.

A second well-studied epigenetically acting lncRNA is the HOX antisense intergenic RNA (*HOTAIR*). *HOTAIR* is transcribed from the *HOXC* gene cluster on chromosome 12 and acts in a repressing manner on 40 kilobases of the *HOXD* cluster on chromosome 2 *in trans* through H3K27 trimethylation [34]. The lncRNA, *Air* and *KCNQ1OT1*, are both localized on imprinted paternal alleles. They recruit the Polycomb Repressive Complex 2 (PRC2) and a histone methylase mediating the enrichment of the histone modification H3K9me3 to silence the genes *KCNQ1* and *IGFR2* [35, 36]. In contrast to lncRNA silencing genes, several activating lncRNAs have been described that promote gene expression of *in cis* target loci with protein-coding genes [37]. *HOXA* transcript at the distal tip (*HOTTIP*) directly interacts *in cis* with the WDR5/MLL complex ending up in the activation of gene transcription from the *HOXA* gene cluster through enrichment of the euchromatin characteristic H3K4me3 flag [38]. The *cis*- and *trans*-chromosomal interaction lncRNA (*CISTR-ACT*) is a chondrogenic regulator that interacts *in cis* and *in trans* with essential developmental genes determining the cartilage. The *CISTR-ACT* lncRNA is transcribed from an enhancer that loops to a 24.4 Mb distant chromosome 12 position to induce *PTH1H* expression. In addition, *CISTR-ACT* pinpoints *SOX9* on the non-homologous chromosome 17 *in trans* [39]. The knowledge about *HOTAIR* and *CISTR-ACT* extend the gene-regulatory background regarding *in cis* interactions. In *in trans* communications of homologous or non-homologous chromosomes, the nuclear architecture is a major participating element.

As far back as 1904, Theodor Boveri coined the term of chromosomal territories [40]. Chromosomes are not randomly distributed within the nucleus, although mitotic conformational changes occur [41]. Transcriptional active euchromatin is predominantly located in the nuclear center; the compact heterochromatin resides in the outer nucleus. The positioning of chromosomes and their interaction is not predetermined, but rather is a result of a stochastically calculated process, including chromosome looping [42]. In the molecular genetic high-



throughput techniques, a modification of chromosome conformation capture (3C) termed Hi-C and Chromatin Interaction Analysis by Paired-End Tag Sequencing (ChIA-PET) are methods that allow proximal chromosomal contacts to be identified. The experimental analysis determined the spatial proximity of gene-rich regions and chromosomes and showed the segregation of euchromatin and heterochromatin genomic areas [43, 44]. The topological nuclear domains can determine tissue-specific gene regulation through different sizes and attributes.

Some lncRNAs have been intensively investigated during the last two decades (Table 1). The data yielded insight into the highly organized structure of the nucleus. The complex interplay between chromosome territories, chromatin state and lncRNAs affects the tissue-specific gene regulation to control developmental stages or to maintain tissue perpetuation [41]. The lncRNAs can reflect nuclear addresses acting in a local, locus-specific or allele-specific manner for the control of gene expression, genome organization or regulation. The initial lncRNAs transcription signals in *cis* or in *trans* and recruits chromatin modifying complexes or basic factors of the transcription machinery. Moreover, the lncRNAs transcription can be involved in the formation of topological nuclear domains, thereby working secondarily on gene regulation [45]. The described lncRNAs-mediated regulation scenarios are maintained from different classes of lncRNAs that belong to the families of competing endogenous lncRNAs (ceRNAs), activating or enhancer-like lncRNAs, Natural Antisense Transcript lncRNAs (NAT) and small nucleolar RNAs (snoRNAs, Table 1). Table 1 lists lncRNAs with defined biological functions or with a proven association with human diseases.

### **Functional insights in lncRNA-mediated gene regulation**

We are merely at the beginning in our understanding of the functional processes and the biological width of lncRNA-mediated gene regulation. One controversial question is how

lncRNAs can specifically regulate its target genes. Do scaffolds between lncRNAs and mediating protein complexes exist to guarantee the *in cis* and *in trans* regulations? Are triple-helices of lncRNAs:DNA:DNA formed or do lncRNAs bind transcription factors and mediate gene expression themselves? During chromatin looping, are lncRNAs dropped from their transcription site for a specific and direct lncRNAs:DNA binding at regulatory sites within a coding gene locus? Do lncRNAs bind the mRNA transcript for post-transcriptional modifications?

The features of lncRNAs for biologically relevant regulatory processes are their keys to success. Several lncRNAs function as decoys to trap regulatory proteins. DNA-damage mediated the induction of the lncRNA *PANDA* that interacted with the transcription factor NF-YA, to prevent apoptosis by titrating the NF-YA away from target genes. The expression control of pro-apoptotic genes can be a general feature of genes that drive mitosis and which promoters harbor lncRNAs [46], (Fig. 2 a). LncRNAs can provide the service as scaffolding adaptors to bind protein complexes for further gene targeting (Fig. 2 b). The lncRNA, *TERC*, serves as scaffold to transport the telomerase complex [47]. Promoter-associated RNA (*pRNA*) associate with the chromatin remodeling complex NoRC/TIP5 to induce transcriptional silencing through DNA methylation of rRNA genes [48]. The DNA methylase, DNMT3b, then recognizes the triple-helix of lncRNA at the DNA binding site for the transcription factor TTF-1 [49]. For *HOTTIP*, Wang et al showed that chromosomal looping with spatial proximity within the *HOXA* gene cluster is necessary to drive transcription of several 5' *HOXA* genes through direct binding of the co-activating *HOTTIP* lncRNA with the adaptor protein WDR5 [38]. Some lncRNAs seem to translate higher spatial chromosome structures and processes such as looping into defined chromatin modifications and domains to control gene expression. The same mechanism could be subject to *CISTR-ACT* and other enhancer-encoded lncRNAs [39, 37], (Fig. 2 c). The physical proximity in chromatin loops enables the transformation of higher

order genome conformation into biochemical histone modifications and transcription factor recruitment. The *lincRNA-p21*, *HOTAIR*, *XIST*, *AIR* and other lncRNAs can bind RNA-binding or chromatin-remodeling proteins to support guiding functions to conduct further remodeling complexes or co-activators or repressors to specific genomic loci [50, 51], (Table 1, Fig. 2 d). *Xist* can stack the transcription factor YY1 that is capable to bind RNA and DNA, thereby attaching *Xist* to the X chromosome. They form the nucleation center together with PRC2 and squelch gene expression by competing with the transcription machinery [52].

### **LncRNAs in development and disease**

In addition to epigenetic functions during X-chromosome inactivation, imprinting and co-activation or repression of genes, lncRNAs have been attributed to various functions in cellular homeostasis, during development and in pathogenesis of diseases. The half-STAU1-binding site RNA ( $\frac{1}{2}$ -sbsRNA) co-activate the STAU1-mediated mRNA decay by dsRNA formation to regulate the degradation of translationally active mRNAs [53]. The terminal differentiation-induced lncRNA (*TINCR*) regulates the somatic tissue differentiation through binding to differentiation-mediating mRNAs for proper translation [54]. *TINCR* directly binds to the STAU1 protein, thereby stabilizing differentiating mRNAs. *Braveheart* (*Bvht*) was identified as lncRNA responsible for the establishment of the cardiovascular lineage determination and the maintenance of the cardiac fate [55]. *Bvht* conducts its functions through interaction with SUZ12, an important subunit of PRC2. *EGO* (eosinophil granule ontogeny) plays a role during eosinophil development [56]. *Fendrr* is a lateral mesoderm-specific lncRNA controlling mesodermal differentiation and its developing derivatives heart and body wall through binding to the histone-remodeling complexes PRC2 and TrxG/MLL [57]. *Fendrr*-lacking embryos showed dysregulation of mesoderm-specific transcription factors and reduction of PRC2 enrichment at their loci. *Gomafu* is involved in neuronal and retinal

development. Its down regulation, the binding of splicing factors and the resulting altered splicing patterns was associated with schizophrenia [58]. The muscle-specific lncRNA *linc-MDI* is a competing endogenous RNA (ceRNA) that controls muscle differentiation via sponging of miRNA. Moreover, *linc-MDI* seem to be involved in the pathogenesis of Duchenne muscle dystrophy [59]. The lncRNA, *FMR4*, triggers the ratio of proliferation and apoptosis and was silenced in patients with the fragile X-syndrome [60]. *CISTR-ACT* was dysregulated due to chromosomal translocations in two different families with the autosomal-dominant Mendelian disorder of the chondrodysplasia brachydactyly type E (BDE). Chromosome 12 translocations physically disrupted *CISTR-ACT* from the major chondrogenic morphogene, *PTH1H*, and caused dysregulation of the coding gene and lncRNA [39]. These data underscore the important interface between genome conformation and gene-lncRNA-regulation. The suppression of *UBE3A-ATS* can activate *UBE3A* in patients with the neurogenetic disorder of the Angelman's syndrome [61, 62]. The severe phenotypes of leukemia, myelofibrosis, sarcoma, and vasculitis were detected in *Xist*-depleted mice and suggest *Xist*-mediated *in vivo* cancer repression. The loss of *Xist* seemed to reactivate the X chromosome leading finally through aberrant hematopoietic stem cells to cancer [63]. The metastasis-associated lung adenocarcinoma transcript 1 (*MALAT1*) that is very abundantly expressed, co-localizes with splicing factors in the nuclear speckles and regulates alternative splicing of pre-mRNAs [64]. Its association with migration, metastasis and tumor growth in lung adenocarcinoma has been shown [65, 66]. *MALAT1* is required for mitotic proliferation and seems to mediate its activity positively through activated p53 and B-MYB, an oncogenic transcription factor. Thus, the dysregulation of splicing factors and alternative splicing led to the dysregulation of cell-cycle-regulated transcription factors promoting cellular proliferation [66]. For the non-polyadenylated *MALAT1*, a 3' triple helix formation was found that served as translational enhancer, and was inhibited by miRNAs, and argued for major role in regulation and stabilization of *MALAT1* [67]. *HOTAIR* was proposed as diagnostic marker in breast and

colorectal cancer. Its depletion resulted in reduced invasiveness and its expression level correlated with differentially regulated genes of the PRC2 complex [68, 25]. Currently, upregulated *HOTTIP* and *HOXA13* expression were associated with prognosis and progression of the hepatocellular carcinoma (HCC), [69]. The highly up-regulated in liver cancer lncRNA *HULC* was found in blood of HCC patients, promising a potential biomarker [70]. *HULC* sponges several miRNA such as miR-372, leading to transcriptional inhibition of target genes, i.e. the transcription factor CREB. The CREB motif within the *HULC* promoter supports CREB-mediated upregulation in liver cancer through an auto-regulatory mechanism blocking the miR-372 function [71]. Moreover, *HULC* correlated with upregulated hepatitis B virus X protein (HBx) that importantly contributes to HCC and that was able to promote *HULC* expression. The *HULC*-mediated downregulation of the tumor suppressor p18 supported the HCC proliferation [72]. The expression of *BACE1* antisense transcript (*BACE1-AS*) was linked to increased amyloid- $\beta$  1-42 in patients with Alzheimer's disease and gave rise for a stabilizing function of the lncRNA [73]. Aberrant *ANRIL* transcripts and mutations were associated with cardiovascular disease and cancer [74, 75]. The existence of linear and circular *ANRIL* transcripts was found in patients with arteriosclerosis [74]. The prostate cancer-associated ncRNA transcript 1 lncRNA *PCAT-1* [76, 77], *SchlAPI* (second chromosome locus associated with prostate-1) [78] and *CTBP1-AS* [79], indicate cancer cell invasiveness and metastasis in prostate cancer progression. *SchlAPI* antagonizes the tumor-suppressing functions of the SWI/SNF chromatin-remodeling complex [80, 78], and *CTBP1-AS* represses *CTBP* by interacting with histone deacetylases and the transcriptional repressor PSF, but also by inhibiting tumor-suppressor genes in a general manner [79].

## Current research directions

The idea that lncRNAs are nuclear addresses or addressors, respectively plays a major role in gene and genome regulation. The regulation of the regulators is not clear. The lncRNA also need to be directed. One hypothesis is that the interplay between the marginally expressed lncRNAs, tissue-specific TF, and histone modifications ensure tissue-specific gene expression. In which extent is stochastic coincidence present? In the human genome, 46 chromosomes containing  $\sim 3 \times 10^9$  basepairs communicate while underlying dramatic conformational changes during mitosis. However, the cellular and nuclear infrastructures remain to fulfill the particularized cellular tasks.

The lncRNAs are often highly tissue-specific. Despite the barely understood mechanisms of their specific target-gene regulation, lncRNAs have a potential therapeutic value. To date, most of the therapeutic agents serve an inhibitory function. Blocking lncRNAs could lead to the upregulation of genes and have a stimulatory effect. The subclass of Natural Antisense Transcripts (NAT), shown in Table 1, can be degraded or inhibited in binding their target mRNA through single-stranded antagonistic oligo-nucleotides (antagoNATs), [81]. The endogenous de-repression of genes could be the key in various haplo-insufficiencies. Moreover, upregulated lncRNAs in cancer that normally exhibit decoy functions could be also targets for antagoNATs [81]. Previously, antisense oligo-nucleotides (ASOs) were successfully applied to silence the RNA gain-of-function effect in the hereditary degenerative disease myotonic dystrophy type 1 (DM1) and a performed myogenic long-term *Malat1* knockdown was effective [82]. Currently, siRNAs are being introduced therapeutically in patients.

Detailed systems-biological approaches are needed to locate, to annotate and to characterize lncRNAs in development and disease. Various genetic model systems have to be established to understand the functional roles of lncRNAs:protein interactions that modulate chromatin remodeling complexes, gene and genome regulation to investigate lncRNA-

associated pathogenesis of disease or developmental defects. In two different projects generating *Malat1* knockout mice, any apparent phenotype or alteration of the murine development was observed [83, 84]. Only *in cis* genes of *Malat1* were differentially expressed [84]. The lncRNA *NEAT1* is highly expressed in the mammal-specific nuclear paraspeckles<sup>4</sup>. Interestingly, the *NEAT1*-depleted mice had no phenotypes, suggesting environmentally provoked nuclear structures [85]. In *Malat1*-depleted mice, showing no phenotype again, *Neat1* was downregulated in several tissues lacking *Malat1*, indicating its dispensability in mice paraspeckles [86]. These data indicate that human-specific lncRNAs may exist that do not exert their human functions in animal models. In contrast, a *Hotair*-deletion in mouse was associated with malformation of spine and metacarpals and a general, non-selective derepression of genes [87]. In the latest study of 18 knockout models for approved lncRNAs, only 5 displayed apparent phenotypes [88]. The results indicate that long-term and more precise phenotypization could reveal additional subtle and highly tissue-specific behavioral phenotypes. The lncRNAs that have been associated with clinically apparent phenotypes are only the tip of the iceberg. The detailed molecular analysis of lncRNAs will augment the understanding of the nuclear regulation networks and discover more pathogenic lncRNAs or circRNAs that can serve as clinically relevant prognostic or diagnostic biomarker or as therapeutic targets.

## Acknowledgements

We apologize to all scientists whose important work of lncRNAs could not be cited in this review. The German Research Foundation (DFG MA-5028/1-3) supports our work. We

---

<sup>4</sup> A paraspeckle is an irregularly shaped cell compartment, approximately 0.2-1  $\mu\text{m}$  in size, found in the nuclear interchromatin space.

also receive support from the ECRC, a joint cooperation between the Max-Delbrück-Center for Molecular Medicine (MDC) and the Medical Faculty of the Charité.

### Conflict of interest

The authors declare no interest conflicts.

**Table 1.** Biological functions and associations of lncRNAs in Mendelian diseases, cancers, cardiovascular and neurological diseases. NAT = natural antisense transcript.

| <b>Development, cellular maintenance and imprinting</b> |   |          |
|---|---|----------|
| <i>1/2-sbsRNA</i>                                       | mRNA degradation; transactivation of STAU1 for mRNA binding   | [53]     |
| <i>Air</i>  | chromatin remodeling; mono-allelic expression; imprinting and silencing of gene loci <i>in cis</i> in murine placenta | [35]     |
| <i>Braveheart</i>                                       | determination of the cardiac lineage in mouse   | [55]     |
| <i>EGO</i>  | regulation of eosinophil differentiation  | [56]     |
| <i>Fendrr</i>   | expression in the murine lateral mesoderm; heart and body wall development  | [57]     |
| <i>Gomafu</i>   | CNS neurons; neuronal stem cell development; Schizophrenia  | [58]     |
| <i>HOTAIRM1</i>   | myelopoiesis; modulation of the expression of the <i>HOXA</i> cluster   | [89]     |
| <i>Jpx</i>  | X-inactivation; activation of <i>XIST</i> , probably through interference with <i>Tsix</i>                            | [33]     |
| <i>LincRNA-EPS</i>                                      | repression of the erythroid differentiation and stimulation of apoptosis  | [90]     |
| <i>Linc-MD1</i>   | competing endogenous lncRNA (ceRNA); control of myelopoiesis, decoy for <i>miR-133</i> and <i>miR-135</i>             | [59]     |
| <i>pRNA</i>   | RNA-dependent DNA-methylation and triplex-formation   | [49]     |
| <i>utNgn1</i>   | enhancer-encoded lncRNA; transcriptional regulation of <i>Neurog1</i>   | [91]     |
| <i>TINCR</i>  | control of somatic tissue differentiation   | [54]     |
| <i>Tsix</i>   | repression of <i>Xist</i> through transcriptional interference  | [31, 92] |
| <i>Xite</i>   | co-activator of the <i>Tsix</i> expression  | [93]     |




| <b>Mendelian diseases</b> |  |                           |
|---------------------------|--|---------------------------|
| <i>CISTR-ACT</i>          | enhancer-encoded lncRNA; chromatin-remodeling; transcriptional co-activation and repression of chondrogenesis genes; upregulation in translocations of chromosome 12, associated with brachydactyly type E | [39]                      |
| <i>FMR4</i>               | anti-apoptotic function; fragile-X-syndrome  | [60]                      |
| <i>HELLPAR</i>            | activation of cellcycle genes; HELLP-syndrome  | [94]                      |
| <i>PRINS</i>              | protective functions for stressed cells in psoriasis   | [95]                      |
| <i>UBE3A-ATS</i>          | imprinting of <i>UBE3A</i> ; Angelman syndrome   | [61, 62]                  |
| <b>Cancer</b>             |  |                           |
| <i>ANRASSF1</i>           | transcriptional co-repressor of the tumor suppressor <i>RASSF1A</i> ; enhancement of the cell proliferation  | [96]                      |
| <i>ANRIL/p15AS</i>        | chromatin remodeling; PCR1-mediated repression of the tumor suppressor <i>INK4A-ARF-INK4b</i> ; cardio-vascular diseases; upregulation in prostate carcinoma; leukemia; mutations are known                | [74, 97, 98, 75, 99, 100] |
| <i>CTBPI-AS</i>           | transcriptional repression of <i>CTBPI</i> ; stimulation of proliferation; Prostate carcinoma  | [79]                      |
| <i>H19</i>                | transcriptional repression; imprinting; expression stimulates proliferation; upregulation in stomach cancers, miRNA regulation   | [101-104]                 |
| <i>HOTAIR</i>             | chromatin remodeling; transcription at the <i>HOXC</i> gene cluster and repression of the <i>HOXD</i> cluster; upregulation in breast and colon cancers; promotion of metastasis                           | [68, 25, 87, 34, 105]     |
| <i>HOTTIP</i>             | chromatin remodeling; transcriptional co-activation of the <i>HOXA</i> gene cluster; potentially involved in leukemias and hepatocellular carcinoma  | [69, 38]                  |
| <i>HULC</i>               | post-transcriptional modification; upregulation in hepatocellular carcinoma  | [106, 70]                 |


|                                |   |                              |
|--------------------------------|---|------------------------------|
| <i>LincRNA-p21</i>             | transcriptional co-activation; p53 regulation after DNA damage; NAT;<br>upregulation in tumor cell lines                            | [50, 51]                     |
| <i>KNCQ1OT1</i>                | chromatin remodeling; loss of imprinting in colorectal carcinoma  | [107,<br>108]                |
| <i>MALAT1</i>                  | post-transcriptional modification; control of alternative splicing; upregulation<br>in tumor tissues; also known as <i>NEAT2</i>    | [109, 65,<br>64, 66,<br>110] |
| <i>PCA3</i>                    | control of prostate carcinoma cells; modulation of androgen receptor signals  | [111]                        |
| <i>PCAT-1</i>                  | stimulation of proliferation; prostate and colorectal carcinoma; biomarker  | [76, 77]                     |
| <i>PTENP1</i>                  | pseudo-gene, that regulates the tumor suppressor <i>PTEN</i> through competitive<br>miRNA binding; complete loss in several cancers | [112]                        |
| <i>SChLAP1</i>                 | promotes invasiveness and metastasis of prostate cancers  | [78]                         |
| <i>SRA</i>                     | transkriptional co-activator of steroid receptors; upregulated during breast<br>cancerogenesis                                      | [113,<br>114]                |
| <i>TERRA</i>                   | protein inhibition (telomerase); promotion of telomeric hetero-chromatin<br>formation; repressed in tumor cell lines                | [115]                        |
| <i>Xist</i>                    | chromatin remodeling; X-inactivation; blocked in breast, ovarian and cervix<br>cancer cell lines; Leukemia                          | [26, 63]                     |
| <b>Cardiovascular diseases</b> |   |                              |
| <i>Alc1-as / cTNI-<br/>as</i>  | co-repressor; NAT; post-transcriptional regulation; involved in Tetralogy of<br>Fallot, ischemia, Heart insufficiency               | [116]                        |
| <i>MIAT / RNCR2</i>            | retina development; Myocard infarction  | [117,<br>118]                |
| <i>Myh7-as</i>                 | co-repressor; NAT; regulation of the expression ratio of the sarcomeric<br>components <i>Myh6</i> and <i>Myh7</i>                   | [119]                        |
| <b>Neurological diseases</b>   |   |                              |

|                 |   |       |
|-----------------|---|-------|
| <i>BACE1-AS</i> | regulation of the mRNA stability and transcriptional co-activation of <i>BACE1</i> ; NAT; upregulation in Alzheimer's disease | [73]  |
| <i>DISC2</i>    | transcriptional regulation of <i>DISC1</i> ; NAT; Schizophrenia   | [120] |
| <i>PINK1-AS</i> | insulin signaling PTEN, Diabetes  | [121] |
| <i>SCA8</i>     | transcriptional repression of <i>KLHL1</i> ; Spinocerebellar ataxia   | [122] |

## Figures.



**Fig. 1. a** Scheme of gene-regulatory elements influencing gene expression. Enhancer, silencer and insulator elements can be localized up to 1.5 Mb upstream or downstream of the transcription start site. Response elements within gene promoters bind transcription factors and co-activators to maintain a tissue-specific gene expression. The regulation is dependent on the histone modifications. **b** Chromatin-looping between a *cis*-regulatory element (CRE) and its target gene promoter. Recruited modifying, mediating, activating or repressing proteins build the transcription factor – co-activator - complex (TFCC) and interact in physical proximity with the promoter to regulate gene expression.



**Fig. 2.** **a** lncRNA can serve as decoys to control the actions of DNA-binding proteins, i.e. *PANDA*. **b** Scaffold structures of lncRNA with protein partners display functional units for gene regulation, *TERC*. **c** Enhancer-encoded lncRNA act specifically on their target genes through chromatin loops, i.e. *CISTR-ACT* and *HOTTIP*. **d** Either DNA-bound adaptor-proteins bind lncRNA or DNA-bound lncRNA serve as guides for further functional processes, i.e. *Xist* or *HOTAIR*. Triple-helix formations of lncRNA with the DNA double helix are possible.

## References

1. C. H. Waddington. 2012. The epigenotype. 1942. *Int J Epidemiol* 41:10-3.
2. T. R. Mercer and J. S. Mattick. 2013. Understanding the regulatory and transcriptional complexity of the genome through structure. *Genome Res* 23:1081-8.
3. K. Chen and N. Rajewsky. 2007. The evolution of gene regulation by transcription factors and microRNAs. *Nat Rev Genet* 8:93-103.
4. M. G. Poulos, R. Batra, K. Charizanis and M. S. Swanson. 2011. Developments in RNA splicing and disease. *Cold Spring Harb Perspect Biol* 3:a000778.
5. J. E. Phillips-Cremins and V. G. Corces. 2013. Chromatin insulators: linking genome organization to cellular function. *Mol Cell* 50:461-74.
6. D. T. Odom, et al. 2007. Tissue-specific transcriptional regulation has diverged significantly between human and mouse. *Nat Genet* 39:730-2.
7. T. Vavouri, K. Walter, W. R. Gilks, B. Lehner and G. Elgar. 2007. Parallel evolution of conserved non-coding elements that target a common set of developmental regulatory genes from worms to humans. *Genome Biol* 8:R15.
8. T. Vavouri, G. K. McEwen, A. Woolfe, W. R. Gilks and G. Elgar. 2006. Defining a genomic radius for long-range enhancer action: duplicated conserved non-coding elements hold the key. *Trends Genet* 22:5-10.
9. D. Schubeler, C. Francastel, D. M. Cimborra, A. Reik, D. I. Martin and M. Groudine. 2000. Nuclear localization and histone acetylation: a pathway for chromatin opening and transcriptional activation of the human beta-globin locus. *Genes Dev* 14:940-50.
10. M. Vignali, A. H. Hassan, K. E. Neely and J. L. Workman. 2000. ATP-dependent chromatin-remodeling complexes. *Mol Cell Biol* 20:1899-910.
11. T. Kouzarides. 2007. Chromatin modifications and their function. *Cell* 128:693-705.

12. E. M. Blackwood and J. T. Kadonaga. 1998. Going the distance: a current view of enhancer action. *Science* 281:60-3.
13. J. T. Lee and M. S. Bartolomei. 2013. X-inactivation, imprinting, and long noncoding RNAs in health and disease. *Cell* 152:1308-23.
14. S. L. Berger. 2002. Histone modifications in transcriptional regulation. *Curr Opin Genet Dev* 12:142-8.
15. J. S. Lee, E. Smith and A. Shilatifard. 2010. The language of histone crosstalk. *Cell* 142:682-5.
16. D. A. Kleinjan and V. van Heyningen. 2005. Long-range control of gene expression: emerging mechanisms and disruption in disease. *Am J Hum Genet* 76:8-32.
17. P. J. Wijchers and W. de Laat. 2011. Genome organization influences partner selection for chromosomal rearrangements. *Trends Genet* 27:63-71.
18. B. Maher. 2012. ENCODE: The human encyclopaedia. *Nature* 489:46-8.
19. M. N. Cabili, C. Trapnell, L. Goff, M. Koziol, B. Tazon-Vega, A. Regev and J. L. Rinn. 2011. Integrative annotation of human large intergenic noncoding RNAs reveals global properties and specific subclasses. *Genes Dev* 25:1915-27.
20. M. Guttman, et al. 2009. Chromatin signature reveals over a thousand highly conserved large non-coding RNAs in mammals. *Nature* 458:223-7.
21. T. B. Hansen, T. I. Jensen, B. H. Clausen, J. B. Bramsen, B. Finsen, C. K. Damgaard and J. Kjems. 2013. Natural RNA circles function as efficient microRNA sponges. *Nature* 495:384-8.
22. S. Memczak, et al. 2013. Circular RNAs are a large class of animal RNAs with regulatory potency. *Nature* 495:333-8.
23. A. M. Khalil, et al. 2009. Many human large intergenic noncoding RNAs associate with chromatin-modifying complexes and affect gene expression. *Proc Natl Acad Sci U S A* 106:11667-72.

24. J. L. Rinn and H. Y. Chang. 2012. Genome regulation by long noncoding RNAs. *Annu Rev Biochem* 81:145-66.
25. R. Kogo, et al. 2011. Long noncoding RNA HOTAIR regulates polycomb-dependent chromatin modification and is associated with poor prognosis in colorectal cancers. *Cancer Res* 71:6320-6.
26. C. J. Brown, A. Ballabio, J. L. Rupert, R. G. Lafreniere, M. Grompe, R. Tonlorenzi and H. F. Willard. 1991. A gene from the region of the human X inactivation centre is expressed exclusively from the inactive X chromosome. *Nature* 349:38-44.
27. M. E. Dinger, et al. 2008. Long noncoding RNAs in mouse embryonic stem cell pluripotency and differentiation. *Genome Res* 18:1433-45.
28. A. Pauli, J. L. Rinn and A. F. Schier. 2011. Non-coding RNAs as regulators of embryogenesis. *Nat Rev Genet* 12:136-49.
29. J. M. Engreitz, et al. 2013. The Xist lncRNA exploits three-dimensional genome architecture to spread across the X chromosome. *Science* 341:1237973.
30. M. D. Simon, et al. 2013. High-resolution Xist binding maps reveal two-step spreading during X-chromosome inactivation. *Nature* 504:465-9.
31. J. T. Lee, L. S. Davidow and D. Warshawsky. 1999. Tsix, a gene antisense to Xist at the X-inactivation centre. *Nat Genet* 21:400-4.
32. D. Tian, S. Sun and J. T. Lee. 2010. The long noncoding RNA, Jpx, is a molecular switch for X chromosome inactivation. *Cell* 143:390-403.
33. S. Sun, B. C. Del Rosario, A. Szanto, Y. Ogawa, Y. Jeon and J. T. Lee. 2013. Jpx RNA activates Xist by evicting CTCF. *Cell* 153:1537-51.
34. J. L. Rinn, et al. 2007. Functional demarcation of active and silent chromatin domains in human HOX loci by noncoding RNAs. *Cell* 129:1311-23.

35. T. Nagano, J. A. Mitchell, L. A. Sanz, F. M. Pauler, A. C. Ferguson-Smith, R. Feil and P. Fraser. 2008. The Air noncoding RNA epigenetically silences transcription by targeting G9a to chromatin. *Science* 322:1717-20.
36. R. R. Pandey, T. Mondal, F. Mohammad, S. Enroth, L. Redrup, J. Komorowski, T. Nagano, D. Mancini-Dinardo and C. Kanduri. 2008. Kcnq1ot1 antisense noncoding RNA mediates lineage-specific transcriptional silencing through chromatin-level regulation. *Mol Cell* 32:232-46.
37. U. A. Orom, et al. 2010. Long noncoding RNAs with enhancer-like function in human cells. *Cell* 143:46-58.
38. K. C. Wang, et al. 2011. A long noncoding RNA maintains active chromatin to coordinate homeotic gene expression. *Nature* 472:120-4.
39. P. G. Maass, et al. 2012. A misplaced lncRNA causes brachydactyly in humans. *J Clin Invest* 122:3990-4002.
40. H. Strickfaden, A. Zunhammer, S. van Koningsbruggen, D. Kohler and T. Cremer. 2010. 4D chromatin dynamics in cycling cells: Theodor Boveri's hypotheses revisited. *Nucleus* 1:284-97.
41. T. Cremer and M. Cremer. 2010. Chromosome territories. *Cold Spring Harb Perspect Biol* 2:a003889.
42. W. A. Bickmore. 2013. The spatial organization of the human genome. *Annu Rev Genomics Hum Genet* 14:67-84.
43. M. J. Fullwood, et al. 2009. An oestrogen-receptor-alpha-bound human chromatin interactome. *Nature* 462:58-64.
44. E. Lieberman-Aiden, et al. 2009. Comprehensive mapping of long-range interactions reveals folding principles of the human genome. *Science* 326:289-93.
45. P. J. Batista and H. Y. Chang. 2013. Long noncoding RNAs: cellular address codes in development and disease. *Cell* 152:1298-307.



46. T. Hung, et al. 2011. Extensive and coordinated transcription of noncoding RNAs within cell-cycle promoters. *Nat Genet* 43:621-9.
47. D. C. Zappulla and T. R. Cech. 2006. RNA as a flexible scaffold for proteins: yeast telomerase and beyond. *Cold Spring Harb Symp Quant Biol* 71:217-24.
48. C. Mayer, K. M. Schmitz, J. Li, I. Grummt and R. Santoro. 2006. Intergenic transcripts regulate the epigenetic state of rRNA genes. *Mol Cell* 22:351-61.
49. K. M. Schmitz, C. Mayer, A. Postepska and I. Grummt. 2010. Interaction of noncoding RNA with the rDNA promoter mediates recruitment of DNMT3b and silencing of rRNA genes. *Genes Dev* 24:2264-9.
50. M. Huarte, et al. 2010. A large intergenic noncoding RNA induced by p53 mediates global gene repression in the p53 response. *Cell* 142:409-19.
51. J. H. Yoon, et al. 2012. LincRNA-p21 suppresses target mRNA translation. *Mol Cell* 47:648-55.
52. Y. Jeon and J. T. Lee. 2011. YY1 tethers Xist RNA to the inactive X nucleation center. *Cell* 146:119-33.
53. C. Gong and L. E. Maquat. 2011. lncRNAs transactivate STAU1-mediated mRNA decay by duplexing with 3' UTRs via Alu elements. *Nature* 470:284-8.
54. M. Kretz, et al. 2013. Control of somatic tissue differentiation by the long non-coding RNA TINCR. *Nature* 493:231-5.
55. C. A. Klattenhoff, et al. 2013. Braveheart, a long noncoding RNA required for cardiovascular lineage commitment. *Cell* 152:570-83.
56. L. A. Wagner, C. J. Christensen, D. M. Dunn, G. J. Spangrude, A. Georgelas, L. Kelley, M. S. Esplin, R. B. Weiss and G. J. Gleich. 2007. EGO, a novel, noncoding RNA gene, regulates eosinophil granule protein transcript expression. *Blood* 109:5191-8.
57. P. Grote, et al. 2013. The tissue-specific lncRNA Fendrr is an essential regulator of heart and body wall development in the mouse. *Dev Cell* 24:206-14.

58. G. Barry, et al. 2013. The long non-coding RNA Gomafu is acutely regulated in response to neuronal activation and involved in schizophrenia-associated alternative splicing. *Mol Psychiatry*.
59. M. Cesana, D. Cacchiarelli, I. Legnini, T. Santini, O. Sthandier, M. Chinappi, A. Tramontano and I. Bozzoni. 2011. A long noncoding RNA controls muscle differentiation by functioning as a competing endogenous RNA. *Cell* 147:358-69.
60. A. M. Khalil, M. A. Faghihi, F. Modarresi, S. P. Brothers and C. Wahlestedt. 2008. A novel RNA transcript with antiapoptotic function is silenced in fragile X syndrome. *PLoS ONE* 3:e1486.
61. M. Landers, M. A. Calciano, D. Colosi, H. Glatt-Deeley, J. Wagstaff and M. Lalande. 2005. Maternal disruption of Ube3a leads to increased expression of Ube3a-ATS in trans. *Nucleic Acids Res* 33:3976-84.
62. L. Meng, R. E. Person and A. L. Beaudet. 2012. Ube3a-ATS is an atypical RNA polymerase II transcript that represses the paternal expression of Ube3a. *Hum Mol Genet* 21:3001-12.
63. E. Yildirim, J. E. Kirby, D. E. Brown, F. E. Mercier, R. I. Sadreyev, D. T. Scadden and J. T. Lee. 2013. Xist RNA is a potent suppressor of hematologic cancer in mice. *Cell* 152:727-42.
64. V. Tripathi, et al. 2010. The nuclear-retained noncoding RNA MALAT1 regulates alternative splicing by modulating SR splicing factor phosphorylation. *Mol Cell* 39:925-38.
65. L. H. Schmidt, et al. 2011. The long noncoding MALAT-1 RNA indicates a poor prognosis in non-small cell lung cancer and induces migration and tumor growth. *J Thorac Oncol* 6:1984-92.
66. V. Tripathi, et al. 2013. Long noncoding RNA MALAT1 controls cell cycle progression by regulating the expression of oncogenic transcription factor B-MYB. *PLoS Genet* 9:e1003368.

67. J. E. Wilusz, C. K. JnBaptiste, L. Y. Lu, C. D. Kuhn, L. Joshua-Tor and P. A. Sharp. 2012. A triple helix stabilizes the 3' ends of long noncoding RNAs that lack poly(A) tails. *Genes Dev* 26:2392-407.
68. R. A. Gupta, et al. 2010. Long non-coding RNA HOTAIR reprograms chromatin state to promote cancer metastasis. *Nature* 464:1071-6.
69. L. Quagliata, et al. 2013. lncRNA HOTTIP / HOXA13 expression is associated with disease progression and predicts outcome in hepatocellular carcinoma patients. *Hepatology*.
70. K. Panzitt, et al. 2007. Characterization of HULC, a novel gene with striking up-regulation in hepatocellular carcinoma, as noncoding RNA. *Gastroenterology* 132:330-42.
71. J. Wang, X. Liu, H. Wu, P. Ni, Z. Gu, Y. Qiao, N. Chen, F. Sun and Q. Fan. 2010. CREB up-regulates long non-coding RNA, HULC expression through interaction with microRNA-372 in liver cancer. *Nucleic Acids Res* 38:5366-83.
72. Y. Du, G. Kong, X. You, S. Zhang, T. Zhang, Y. Gao, L. Ye and X. Zhang. 2012. Elevation of highly up-regulated in liver cancer (HULC) by hepatitis B virus X protein promotes hepatoma cell proliferation via down-regulating p18. *J Biol Chem* 287:26302-11.
73. M. A. Faghihi, et al. 2008. Expression of a noncoding RNA is elevated in Alzheimer's disease and drives rapid feed-forward regulation of beta-secretase. *Nat Med* 14:723-30.
74. C. E. Burd, W. R. Jeck, Y. Liu, H. K. Sanoff, Z. Wang and N. E. Sharpless. 2010. Expression of linear and novel circular forms of an INK4/ARF-associated non-coding RNA correlates with atherosclerosis risk. *PLoS Genet* 6:e1001233.
75. E. Pasmant, I. Laurendeau, D. Heron, M. Vidaud, D. Vidaud and I. Bieche. 2007. Characterization of a germ-line deletion, including the entire INK4/ARF locus, in a melanoma-neural system tumor family: identification of ANRIL, an antisense noncoding RNA whose expression coclusters with ARF. *Cancer Res* 67:3963-9.

76. X. Ge, Y. Chen, X. Liao, D. Liu, F. Li, H. Ruan and W. Jia. 2013. Overexpression of long noncoding RNA PCAT-1 is a novel biomarker of poor prognosis in patients with colorectal cancer. *Med Oncol* 30:588.
77. J. R. Prensner, et al. 2011. Transcriptome sequencing across a prostate cancer cohort identifies PCAT-1, an unannotated lincRNA implicated in disease progression. *Nat Biotechnol* 29:742-9.
78. J. R. Prensner, et al. 2013. The long noncoding RNA SchLAP1 promotes aggressive prostate cancer and antagonizes the SWI/SNF complex. *Nat Genet*.
79. K. Takayama, et al. 2013. Androgen-responsive long noncoding RNA CTBP1-AS promotes prostate cancer. *Embo J* 32:1665-80.
80. P. Lu and C. W. Roberts. 2013. The SWI/SNF tumor suppressor complex: Regulation of promoter nucleosomes and beyond. *Nucleus* 4:374-378.
81. C. Wahlestedt. 2013. Targeting long non-coding RNA to therapeutically upregulate gene expression. *Nat Rev Drug Discov* 12:433-46.
82. T. M. Wheeler, A. J. Leger, S. K. Pandey, A. R. MacLeod, M. Nakamori, S. H. Cheng, B. M. Wentworth, C. F. Bennett and C. A. Thornton. 2012. Targeting nuclear RNA for in vivo correction of myotonic dystrophy. *Nature* 488:111-5.
83. M. Eissmann, et al. 2012. Loss of the abundant nuclear non-coding RNA MALAT1 is compatible with life and development. *RNA Biol* 9:1076-87.
84. B. Zhang, et al. 2012. The lncRNA Malat1 is dispensable for mouse development but its transcription plays a cis-regulatory role in the adult. *Cell Rep* 2:111-23.
85. S. Nakagawa, T. Naganuma, G. Shioi and T. Hirose. 2011. Paraspeckles are subpopulation-specific nuclear bodies that are not essential in mice. *J Cell Biol* 193:31-9.
86. S. Nakagawa, J. Y. Ip, G. Shioi, V. Tripathi, X. Zong, T. Hirose and K. V. Prasanth. 2012. Malat1 is not an essential component of nuclear speckles in mice. *RNA* 18:1487-99.

87. L. Li, et al. 2013. Targeted disruption of Hotair leads to homeotic transformation and gene derepression. *Cell Rep* 5:3-12.
88. M. Sauvageau, et al. 2013. Multiple knockout mouse models reveal lincRNAs are required for life and brain development. *Elife* 2:e01749.
89. X. Zhang, et al. 2009. A myelopoiesis-associated regulatory intergenic noncoding RNA transcript within the human HOXA cluster. *Blood* 113:2526-34.
90. W. Hu, B. Yuan, J. Flygare and H. F. Lodish. 2011. Long noncoding RNA-mediated anti-apoptotic activity in murine erythroid terminal differentiation. *Genes Dev* 25:2573-8.
91. M. Onoguchi, Y. Hirabayashi, H. Koseki and Y. Gotoh. 2012. A noncoding RNA regulates the neurogenin1 gene locus during mouse neocortical development. *Proc Natl Acad Sci U S A* 109:16939-44.
92. P. Navarro, et al. 2010. Molecular coupling of Tsix regulation and pluripotency. *Nature* 468:457-60.
93. Y. Ogawa and J. T. Lee. 2003. Xite, X-inactivation intergenic transcription elements that regulate the probability of choice. *Mol Cell* 11:731-43.
94. M. van Dijk, et al. 2012. HELLP babies link a novel lincRNA to the trophoblast cell cycle. *J Clin Invest* 122:4003-11.
95. E. Sonkoly, et al. 2005. Identification and characterization of a novel, psoriasis susceptibility-related noncoding RNA gene, PRINS. *J Biol Chem* 280:24159-67.
96. F. C. Beckedorff, A. C. Ayupe, R. Crocci-Souza, M. S. Amaral, H. I. Nakaya, D. T. Soltys, C. F. Menck, E. M. Reis and S. Verjovski-Almeida. 2013. The intronic long noncoding RNA ANRASSF1 recruits PRC2 to the RASSF1A promoter, reducing the expression of RASSF1A and increasing cell proliferation. *PLoS Genet* 9:e1003705.
97. M. S. Cunnington, M. Santibanez Koref, B. M. Mayosi, J. Burn and B. Keavney. 2010. Chromosome 9p21 SNPs Associated with Multiple Disease Phenotypes Correlate with ANRIL Expression. *PLoS Genet* 6:e1000899.

98. Y. Kotake, T. Nakagawa, K. Kitagawa, S. Suzuki, N. Liu, M. Kitagawa and Y. Xiong. 2011. Long non-coding RNA ANRIL is required for the PRC2 recruitment to and silencing of p15(INK4B) tumor suppressor gene. *Oncogene* 30:1956-62.
99. E. Pasmant, A. Sabbagh, M. Vidaud and I. Bieche. 2011. ANRIL, a long, noncoding RNA, is an unexpected major hotspot in GWAS. *Faseb J* 25:444-8.
100. K. L. Yap, S. Li, A. M. Munoz-Cabello, S. Raguz, L. Zeng, S. Mujtaba, J. Gil, M. J. Walsh and M. M. Zhou. 2010. Molecular interplay of the noncoding RNA ANRIL and methylated histone H3 lysine 27 by polycomb CBX7 in transcriptional silencing of INK4a. *Mol Cell* 38:662-74.
101. T. Arita, et al. 2013. Circulating long non-coding RNAs in plasma of patients with gastric cancer. *Anticancer Res* 33:3185-93.
102. A. N. Kallen, et al. 2013. The Imprinted H19 LncRNA Antagonizes Let-7 MicroRNAs. *Mol Cell* 52:101-12.
103. I. J. Matouk, N. DeGroot, S. Mezan, S. Ayesh, R. Abu-lail, A. Hochberg and E. Galun. 2007. The H19 non-coding RNA is essential for human tumor growth. *PLoS ONE* 2:e845.
104. J. L. Thorvaldsen, K. L. Duran and M. S. Bartolomei. 1998. Deletion of the H19 differentially methylated domain results in loss of imprinted expression of H19 and Igf2. *Genes Dev* 12:3693-702.
105. Z. Yang, L. Zhou, L. M. Wu, M. C. Lai, H. Y. Xie, F. Zhang and S. S. Zheng. 2011. Overexpression of long non-coding RNA HOTAIR predicts tumor recurrence in hepatocellular carcinoma patients following liver transplantation. *Ann Surg Oncol* 18:1243-50.
106. Y. Liu, et al. 2012. A genetic variant in long non-coding RNA HULC contributes to risk of HBV-related hepatocellular carcinoma in a Chinese population. *PLoS ONE* 7:e35145.
107. M. C. Golding, L. S. Magri, L. Zhang, S. A. Lalone, M. J. Higgins and M. R. Mann. 2011. Depletion of Kcnq1ot1 non-coding RNA does not affect imprinting maintenance in stem cells. *Development* 138:3667-78.

108. S. Nakano, et al. 2006. Expression profile of LIT1/KCNQ1OT1 and epigenetic status at the KvDMR1 in colorectal cancers. *Cancer Sci* 97:1147-54.
109. T. Gutschner, et al. 2013. The noncoding RNA MALAT1 is a critical regulator of the metastasis phenotype of lung cancer cells. *Cancer Res* 73:1180-9.
110. C. Xu, M. Yang, J. Tian, X. Wang and Z. Li. 2011. MALAT-1: a long non-coding RNA and its important 3' end functional motif in colorectal cancer metastasis. *Int J Oncol* 39:169-75.
111. G. L. Lee, A. Dobi and S. Srivastava. 2011. Prostate cancer: diagnostic performance of the PCA3 urine test. *Nat Rev Urol* 8:123-4.
112. L. Poliseno, L. Salmena, J. Zhang, B. Carver, W. J. Haveman and P. P. Pandolfi. 2010. A coding-independent function of gene and pseudogene mRNAs regulates tumour biology. *Nature* 465:1033-8.
113. S. M. Colley and P. J. Leedman. 2011. Steroid Receptor RNA Activator - A nuclear receptor coregulator with multiple partners: Insights and challenges. *Biochimie* 93:1966-72.
114. C. Cooper, J. Guo, Y. Yan, S. Chooniedass-Kothari, F. Hube, M. K. Hamedani, L. C. Murphy, Y. Myal and E. Leygue. 2009. Increasing the relative expression of endogenous non-coding Steroid Receptor RNA Activator (SRA) in human breast cancer cells using modified oligonucleotides. *Nucleic Acids Res* 37:4518-31.
115. S. Redon, I. Zemp and J. Lingner. 2013. A three-state model for the regulation of telomerase by TERRA and hnRNPA1. *Nucleic Acids Res* 41:9117-28.
116. O. Ritter, H. Haase, H. D. Schulte, P. E. Lange and I. Morano. 1999. Remodeling of the hypertrophied human myocardium by cardiac bHLH transcription factors. *J Cell Biochem* 74:551-61.
117. N. Ishii, et al. 2006. Identification of a novel non-coding RNA, MIAT, that confers risk of myocardial infarction. *J Hum Genet* 51:1087-99.
118. N. A. Rapicavoli, E. M. Poth and S. Blackshaw. 2010. The long noncoding RNA RNCR2 directs mouse retinal cell specification. *BMC Dev Biol* 10:49.

119. F. Haddad, P. W. Bodell, A. X. Qin, J. M. Giger and K. M. Baldwin. 2003. Role of antisense RNA in coordinating cardiac myosin heavy chain gene switching. *J Biol Chem* 278:37132-8.
120. J. E. Chubb, N. J. Bradshaw, D. C. Soares, D. J. Porteous and J. K. Millar. 2008. The DISC locus in psychiatric illness. *Mol Psychiatry* 13:36-64.
121. C. Scheele, et al. 2007. Altered regulation of the PINK1 locus: a link between type 2 diabetes and neurodegeneration? *Faseb J* 21:3653-65.
122. W. L. Chen, J. W. Lin, H. J. Huang, S. M. Wang, M. T. Su, G. J. Lee-Chen, C. M. Chen and H. M. Hsieh-Li. 2008. SCA8 mRNA expression suggests an antisense regulation of KLHL1 and correlates to SCA8 pathology. *Brain Res* 1233:176-84.